PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy
ConclusionsFour-week persistence of cfDNAPIK3CA mutation appears highly correlated with PFS.Trial registrationNCT01612871, registered on June 6th, 2012;https://clinicaltrials.gov/ct2/show/NCT01612871.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Genetics | Hormonal Therapy | Hormones | Study